Oric Pharmaceuticals/ORIC

$12.08

1.09%
-
1D1W1MYTD1YMAX

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. The Company is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations, and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).

Ticker

ORIC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jacob Chacko

Employees

93

Headquarters

South san francisco, United States

ORIC Metrics

BasicAdvanced
$738.91M
Market cap
-
P/E ratio
-$2.00
EPS
0.97
Beta
-
Dividend rate

What the Analysts think about ORIC

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
33.61% upside
High $27.00
Low $12.00
$12.08
Current price
$16.14
Average price target

ORIC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-25.4M
10.92%
Profit margin
0%
-

ORIC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 4.74%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.52
-$0.53
-$0.50
-$0.44
-
Expected
-$0.54
-$0.54
-$0.57
-$0.46
-$0.49
Surprise
-3.05%
-1.88%
-12.15%
-4.74%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Oric Pharmaceuticals stock

Buy or sell Oric Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing